Chief Financial Officer
Andreas Emmenegger is Chief Financial Officer (CFO) and Co-Entrepreneur of Molecular Partners since 2007. Prior to that, he was CFO of Glycart Biotechnology AG where he had a leading role in the successful CHF 235 million trade sale to F. Hoffmann-La Roche AG in 2005. Mr. Emmenegger was Head of Strategic Alliance Finance (Genentech) for Roche Headquarters, Basel, Switzerland. He has more than 20 years of experience as a CFO of several public and private multinational companies raising over CHF 400 million equity through public and private offerings, including the lead in the successful IPOs at the SIX Swiss Echange of Molecular Partners in 2014 and of Interroll Holding AG in 1997. In addition, Mr. Emmenegger has more than 10 years of international industry experience in banking, capital markets, M&A and human resources. He is also co-founder and member (since 2011) of the board of directors of Piqur Therapeutics AG, Switzerland, a venture-backed privately held biopharmaceutical company. He has been a member of the board of directors of the Luzerner Kantonalbank since May 2016. Mr. Emmenegger holds a degree in finance, economics and business administration as well as an Executive MBA degree from IESE Business School, Barcelona.